Podcast appearances and mentions of ian flinn

Proceedings from an educational event held in partnership with the 2022 Pan Pacific Lymphoma Conference, featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, moderated by Dr Neil Love.

Featuring perspectives from Drs Ajai Chari, Ian Flinn, Nikhil Munshi and Laurie Sehn, including the following topics: Part 1: Case Presentations and Clinical Decision-Making (0:00) Case: A man in his early 70s with diffuse large B-cell lymphoma (DLBCL) arising from follicular lymphoma — Ian W Flinn, MD, PhD (3:46) Case: A man in his late 50s with nongerminal center B-cell-like subtype DLBCL — Laurie H Sehn, MD, MPH (15:57) Case: CAR-T therapy during the pandemic — Nikhil C Munshi, MD (22:16) Case: Anti-BCMC bispecific in triple-class and penta-drug refractory disease — Ajai Chari, MD (33:54) CAR-T therapy for non-Hodgkin lymphoma — Dr Flinn (37:09) Bispecifics for non-Hodgkin lymphoma — Dr Sehn (51:48) CAR-T therapy for multiple myeloma — Dr Munshi (1:13:23) Bispecifics for multiple myeloma — Dr Chari (1:26:14) CME information and select publications

CME credits: 0.25 Valid until: 30-06-2023 Claim your CME credit at https://reachmd.com/programs/cme/tackling-adverse-events-associated-with-disruption-of-b-cell-receptor-signaling-a-multispecialty-approach/13796/ Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent's unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.

CME credits: 0.25 Valid until: 30-06-2023 Claim your CME credit at https://reachmd.com/programs/cme/tackling-adverse-events-associated-with-disruption-of-b-cell-receptor-signaling-a-multispecialty-approach/13796/ Preventing or mitigating adverse events (AEs) when utilizing small molecule inhibitors of BTK and Bcl-2 in the management of CLL is critical to improving patient outcomes. Coupling each agent's unique side-effect profile with the appropriate patient makes the decisions even more complex. Join Drs. Ian Flinn and William Wierda as they deep dive into these issues and offer actionable guidance backed by key clinical trials.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Proceedings from a daylong symposium hosted in partnership with North Carolina Oncology Association and the South Carolina Oncology Society, featuring key clinical presentations and papers in chronic lymphocytic leukemia and lymphomas, multiple myeloma, genitourinary cancers, breast cancer, gastrointestinal cancers and lung cancer. Featuring perspectives from Drs Virginia Borges, Natalie Callander, Robert Dreicer, Ian Flinn, Ramaswamy Govindan, Elizabeth Heath, Howard Hochster, Komal Jhaveri, Melissa Johnson, Ann LaCasce, Wells Messersmith and S Vincent Rajkumar.

Featuring slide presentations and related discussion from Drs Andrew Evens, Ian Flinn and Gilles Salles, including the following topics: Follicular Lymphoma — Andrew Evens, DO, MSc (0:00) Mantle Cell Lymphoma — Ian Flinn, MD, PhD (36:39) Diffuse Large B-Cell Lymphoma — Gilles Salles, MD, PhD (1:03:37) CME information and select publications

Featuring perspectives from Drs Andrew Evens, Ian Flinn and Gilles Salles, including the following topics: Introduction (0:00) Follicular Lymphoma (FL) (1:40) Case: A man in his early 70s with relapsed/refractory (R/R) FL — Andrew M Evens, DO, MSc (6:47) Case: A woman in her late 60s with R/R FL and an EZH2 mutation — Ian W Flinn, MD, PhD (15:00) Mantle Cell Lymphoma (MCL) (21:40) Case: A man in his early 70s with MCL — Dr Flinn (28:51) Case: A woman in her late 60s with MCL who received a Bruton tyrosine kinase inhibitor and received chimeric antigen receptor (CAR) T-cell therapy — Dr Evens (33:18) Case: A man in his early 60s with R/R MCL — Dr Flinn (36:04) Diffuse Large B-Cell Lymphoma (DLBCL) (37:41) Case: A man in his early 80s with R/R DLBCL — Dr Flinn (43:53) Case: A woman in her late 70s with DLBCL — Gilles Salles, MD, PhD (46:46) Case: A man in his late 20s with R/R DLBCL treated with CAR T-cell therapy — Dr Salles (51:00) CME information and select publications

A special audio program developed from a series of webinars held in conjunction with the Society of Hematologic Oncology 2021 Annual Meeting. Featuring perspectives from Drs Andrew Evens, Ian Flinn and Gilles Salles.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.

Go online to PeerView.com/EUU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, two lymphoma experts discuss the newest treatment options for follicular lymphoma (FL). Hear what Drs. John Pagel and Ian Flinn have to say about recent evidence supporting a personalized approach to treating patients with relapsed FL, including the integration and use of novel targeted options, such as PI3K and EZH2 inhibitors. The experts also provide their insights on baseline factors that can help identify patients who may benefit from the use of such innovative agents, as well as safety management. Upon completion of this activity, participants should be better able to: Identify disease- and patient-related factors that can guide therapeutic selection and prognosis in patients with follicular lymphoma, Summarize current safety and efficacy evidence surrounding novel targeted agents in the setting of relapsed/refractory follicular lymphoma, Integrate targeted agents into the management of patients with relapsed follicular lymphoma, Develop a management plan for the unique adverse events associated with the use of novel therapies in the follicular lymphoma setting.